Maxcyte (MXCT) Operating Leases (2020 - 2025)
Historic Operating Leases for Maxcyte (MXCT) over the last 6 years, with Q3 2025 value amounting to $16.8 million.
- Maxcyte's Operating Leases fell 324.49% to $16.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $16.8 million, marking a year-over-year decrease of 324.49%. This contributed to the annual value of $17.2 million for FY2024, which is 444.65% down from last year.
- Per Maxcyte's latest filing, its Operating Leases stood at $16.8 million for Q3 2025, which was down 324.49% from $17.2 million recorded in Q2 2025.
- Maxcyte's Operating Leases' 5-year high stood at $18.0 million during Q4 2023, with a 5-year trough of $500200.0 in Q3 2021.
- For the 5-year period, Maxcyte's Operating Leases averaged around $13.9 million, with its median value being $15.9 million (2022).
- In the last 5 years, Maxcyte's Operating Leases soared by 287317.07% in 2022 and then crashed by 444.65% in 2024.
- Quarter analysis of 5 years shows Maxcyte's Operating Leases stood at $5.2 million in 2021, then skyrocketed by 209.18% to $15.9 million in 2022, then increased by 12.74% to $18.0 million in 2023, then fell by 4.45% to $17.2 million in 2024, then dropped by 1.88% to $16.8 million in 2025.
- Its Operating Leases was $16.8 million in Q3 2025, compared to $17.2 million in Q2 2025 and $17.5 million in Q1 2025.